Standard BioTools
LAB
160 hedge funds and large institutions have $337M invested in Standard BioTools in 2025 Q2 according to their latest regulatory filings, with 29 funds opening new positions, 48 increasing their positions, 44 reducing their positions, and 12 closing their positions.
142% more first-time investments, than exits
New positions opened: 29 | Existing positions closed: 12
39% more call options, than puts
Call options by funds: $68K | Put options by funds: $49K
11% more capital invested
Capital invested by funds: $304M → $337M (+$32.5M)
10% more funds holding
Funds holding: 145 → 160 (+15)
9% more repeat investments, than reductions
Existing positions increased: 48 | Existing positions reduced: 44
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
0.43% less ownership
Funds ownership: 74.3% → 73.87% (-0.43%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LFCM
Long Focus Capital Management
San Juan,
Puerto Rico
|
+$3.74M |
| 2 |
MCO
MAK Capital One
New York
|
+$3.13M |
| 3 |
KLP
Kent Lake PR
Anasco,
Puerto Rico
|
+$1.11M |
| 4 |
Goldman Sachs
New York
|
+$712K |
| 5 |
RA
Royce & Associates
New York
|
+$706K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$4.97M |
| 2 |
Millennium Management
New York
|
-$3.01M |
| 3 |
TM
Tikvah Management
Charlotte,
North Carolina
|
-$1.66M |
| 4 |
Primecap Management
Pasadena,
California
|
-$381K |
| 5 |
GCP
GSA Capital Partners
London,
United Kingdom
|
-$335K |
LAB Hedge Fund Activity: Q2 2025 in Review
160 of the 7,613 institutional investors tracked by Wall St. Rank reported a position in Standard BioTools (LAB) for Q2 2025, worth a combined $337M — up 11% from $304M a quarter earlier.
Buyers outnumbered sellers: 29 funds opened new LAB positions and 12 closed out — a net gain of 17 holders — while 48 added to existing stakes and 44 trimmed.
The largest buyer was Long Focus Capital Management, adding an estimated $3.74M. The largest seller was Morgan Stanley, cutting an estimated $4.97M.
- 160 institutional investors held Standard BioTools (LAB) as of Q2 2025, up from 145 in Q1 2025.
- Funds reported $337M of Standard BioTools stock for Q2 2025, up 11% quarter-over-quarter.
- 29 funds opened new Standard BioTools positions in Q2 2025 and 12 closed out, a net change of +17 holders.
- The largest Standard BioTools buyer in Q2 2025 was Long Focus Capital Management, an estimated $3.74M added.
- The largest Standard BioTools seller in Q2 2025 was Morgan Stanley, an estimated $4.97M sold.
Based on aggregated 13F filings for Q2 2025.